{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T09:35:09Z","timestamp":1774690509988,"version":"3.50.1"},"reference-count":41,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JIR"],"DOI":"10.2147\/jir.s490210","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T07:05:11Z","timestamp":1732518311000},"page":"9697-9710","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Significance of Abnormal Serum LGALS3BP Expression in Patients with Idiopathic Inflammatory Myopathies"],"prefix":"10.2147","volume":"Volume 17","author":[{"given":"Liuyi","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuehong","family":"Lao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenjia","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuting","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1981-9273","authenticated-orcid":true,"given":"Xi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,11]]},"reference":[{"key":"ref1","unstructured":"Plotz PH, Rider Lg Fau - Targoff IN, Targoff In Fau Raben N, Raben N, Fau O\u2019Hanlon TP, Tp Fau \u2013 Miller O. NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy."},{"key":"ref2","unstructured":"Tanboon J, Uruha A, Stenzel W, Nishino I. Where are we moving in the classification of idiopathic inflammatory myopathies? 1473\u20136551."},{"key":"ref3","author":"Mariampillai","journal-title":"JAMA Neurol"},{"key":"ref4","first-page":"2665","author":"Connolly","journal-title":"Lancet Rheumatol"},{"key":"ref5","unstructured":"Mammen AL, Allenbach Y, Stenzel W, Benveniste O 239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. 1873\u20132364."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/8u8p8x","author":"Zanframundo","year":"2024","journal-title":"Clini Experim Rheum"},{"key":"ref7","unstructured":"Lundberg IA-O, Fujimoto MA-O, Vencovsky JA-O, et al. Idiopathic inflammatory myopathies."},{"key":"ref8","unstructured":"Schmidt J Current Classification and Management of Inflammatory Myopathies. 2214\u20133599."},{"key":"ref9","unstructured":"White MJ, Roife D, Gomer RH Galectin-3 Binding Protein Secreted by Breast Cancer Cells Inhibits Monocyte-Derived Fibrocyte Differentiation."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1006\/bbrc.1994.1854","volume":"201","author":"Inohara","year":"1994","journal-title":"Biochem Bioph Rese Commu"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900681","volume":"204","author":"Watanabe","year":"2020","journal-title":"J Immun"},{"key":"ref12","first-page":"1752","author":"Chen","journal-title":"Bioinfo Platform Biol Big-Data Mining"},{"key":"ref13","unstructured":"Zhou X, Zhang Y, Wang N. Systematic identification of key extracellular proteins as the potential biomarkers in lupus nephritis. 1664\u20133224."},{"key":"ref14","unstructured":"Bohan A F, Peter JB, Peter JB Polymyositis and dermatomyositis (first of two parts). 0028\u20134793."},{"key":"ref15","unstructured":"Bohan A F, Peter JB, Peter JB Polymyositis and dermatomyositis (second of two parts). 0028\u20134793."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Resp Crit Care"},{"key":"ref17","unstructured":"Douglas WW, Tazelaar Hd F, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. (1073\u2013449X."},{"key":"ref18","doi-asserted-by":"publisher","author":"Ida","journal-title":"LID","DOI":"10.1136\/rmdopen-2022-002795"},{"key":"ref19","author":"Bianchi","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"ref20","author":"Liang","year":"","journal-title":"Front Cell Develop Biol"},{"key":"ref21","unstructured":"Samarajiwa SA, Forster S, Fau - Auchettl K, Auchettl K, Fau - Hertzog PJ. INTERFEROME: the database of interferon regulated genes. 1362\u20134962."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3390\/s130201664","volume":"13","author":"Qian","year":"2013","journal-title":"Sensors (Basel, Switzerland)"},{"key":"ref23","unstructured":"Wong D, Kea B, Fau - Pesich R, et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. 1932\u20136203."},{"key":"ref24","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, et al. Identification of distinctive interferon gene signatures in different types of myositis. 1526."},{"key":"ref25","unstructured":"Bolko LA-O, Jiang W, Tawara N, et al. The role of interferons type I. II III myositis. 1750\u20133639."},{"key":"ref26","author":"Dufrusine","year":"","journal-title":"Mole Oncolo"},{"key":"ref27","unstructured":"Cela IA-O, Caponio VA-O, Capone E, et al. LGALS3BP is a potential target of antibody-drug conjugates in oral squamous cell carcinoma. 1601\u20131825."},{"key":"ref28","author":"Capone","year":"2024","journal-title":"Oral Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.chemosphere.2012.02.003","volume":"87","author":"Choi","year":"2012","journal-title":"Chemosphere"},{"key":"ref30","author":"Song","year":"2021","journal-title":"Oncogene"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.55563\/clinexprheumatol\/ol0vqj","volume":"39","author":"Peretz","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"ref32","unstructured":"Ding H, Shen Y, Lin C, et al. Urinary galectin-3 binding protein (G3BP) as a biomarker for disease activity and renal pathology characteristics in lupus nephritis. 1478\u20136362."},{"key":"ref33","unstructured":"El Bannoudi HA-O, Cornwell MA-O, Luttrell-Williams E, et al. Platelet LGALS3BP as a Mediator of Myeloid Inflammation in Systemic Lupus Erythematosus. 2326\u20135205."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"158","DOI":"10.55563\/clinexprheumatol\/s364rt","volume":"40","author":"Rasmussen","year":"2022","journal-title":"Clinical and Experimental Rheumatology"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.3390\/ijms24043955","author":"Pesole","year":"","journal-title":"Int J Mol Sci"},{"key":"ref36","unstructured":"Mackinnon AC, Gibbons Ma Fau - Farnworth SL, Farnworth Sl Fau - Leffler H, et al. Regulation of transforming growth factor-\u03b21-driven lung fibrosis by galectin-3. 1535\u20134970."},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02559-2020","author":"Hirani","year":"","journal-title":"LID"},{"key":"ref38","unstructured":"Kogami MA-OX, Abe Y, Ando T, Makiyama A, Yamaji K, Tamura NA-O. Changes in anti-MDA5 antibody titres and serum cytokine levels before and after diagnosis of anti-MDA5 antibody-positive dermatomyositis."},{"key":"ref39","first-page":"2045","author":"Mendes-Frias","year":"","journal-title":"ScienRepor"},{"key":"ref40","first-page":"1873","author":"NTM","year":"2021","journal-title":"J Derma Scie"},{"key":"ref41","author":"De Vooght","year":"2020","journal-title":"Rheumatolo"}],"container-title":["Journal of Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/97645","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/97645","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T07:05:17Z","timestamp":1732518317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/clinical-significance-of-abnormal-serum-lgals3bp-expression-in-patient-peer-reviewed-fulltext-article-JIR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":41,"URL":"https:\/\/doi.org\/10.2147\/jir.s490210","relation":{},"ISSN":["1178-7031"],"issn-type":[{"value":"1178-7031","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}